XML 43 R25.htm IDEA: XBRL DOCUMENT
v3.24.0.1

Revenues (Tables) | 12 Months Ended
--- | ---
Dec. 29, 2023
Revenue from Contract with Customer [Abstract] |
Schedule of Disaggregation of Revenue | Revenues consisted of the following (in thousands):
|  |  | Year Ended December 31,
|  |  |  |  | 2023 |  | 2022 |  | 2021
Product revenues: |  |  |  |  |  |  |  |  |
Gross product revenues |  |  |  |  | $ | 2,272,533 |  |  | $ | 1,951,169 |  |  | $ | 1,452,913 |
Discounts and allowances |  |  |  |  | (643,654) |  |  | (549,926) |  |  | (375,657) |
Net product revenues |  |  |  |  | 1,628,879 |  |  | 1,401,243 |  |  | 1,077,256 |
Collaboration revenues: |  |  |  |  |  |  |  |  |
License revenues |  |  |  |  | 178,635 |  |  | 162,056 |  |  | 249,956 |
Collaboration services revenues |  |  |  |  | 22,694 |  |  | 47,763 |  |  | 107,758 |
Total collaboration revenues |  |  |  |  | 201,329 |  |  | 209,819 |  |  | 357,714 |
Total revenues |  |  |  |  | $ | 1,830,208 |  |  | $ | 1,611,062 |  |  | $ | 1,434,970 |
Net product revenues by product were as follows (in thousands):
|  |  | Year Ended December 31,
|  |  |  |  | 2023 |  | 2022 |  | 2021
CABOMETYX |  |  |  |  | $ | 1,614,942 |  |  | $ | 1,375,909 |  |  | $ | 1,054,050 |
COMETRIQ |  |  |  |  | 13,937 |  |  | 25,334 |  |  | 23,206 |
Net product revenues |  |  |  |  | $ | 1,628,879 |  |  | $ | 1,401,243 |  |  | $ | 1,077,256 |
Schedule of Concentration Risks | The percentage of total revenues by customer who individually accounted for 10% or more of our total revenues were as follows:
| Year Ended December 31,
| 2023 |  | 2022 |  | 2021
Affiliates of AmerisourceBergen Corporation | 17 | % |  | 18 | % |  | 14 | %
Affiliates of McKesson Corporation | 17 | % |  | 17 | % |  | 14 | %
Affiliates of CVS Health Corporation | 17 | % |  | 17 | % |  | 14 | %
Accredo Health, Incorporated | 12 | % |  | 10 | % |  | 9 | %
Affiliates of Optum Specialty Pharmacy | 10 | % |  | 10 | % |  | 8 | %
Ipsen Pharma SAS | 8 | % |  | 10 | % |  | 21 | %
The percentage of trade receivables by customer who individually accounted for 10% or more of our trade receivables were as follows:
| December 31, |  |
| 2023 |  | 2022 |  |
Affiliates of McKesson Corporation | 21 | % |  | 22 | % |  |
Affiliates of CVS Health Corporation | 20 | % |  | 18 | % |  |
Ipsen Pharma SAS | 19 | % |  | 20 | % |  |
Affiliates of AmerisourceBergen Corporation | 17 | % |  | 18 | % |  |
Cardinal Health, Inc. | 11 | % |  | 11 | % |  |
Schedule of Revenues Disaggregated by Geographic Region | Total revenues by geographic region were as follows (in thousands):
|  |  | Year Ended December 31,
|  |  |  |  | 2023 |  | 2022 |  | 2021
U.S. |  |  |  |  | $ | 1,645,749 |  |  | $ | 1,413,743 |  |  | $ | 1,089,396 |
Europe |  |  |  |  | 144,969 |  |  | 168,592 |  |  | 302,073 |
Japan |  |  |  |  | 39,490 |  |  | 28,727 |  |  | 43,501 |
Total revenues |  |  |  |  | $ | 1,830,208 |  |  | $ | 1,611,062 |  |  | $ | 1,434,970 |
Schedule of Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances | The activities and ending reserve balances for each significant category of discounts and allowances (which constitute variable consideration) were as follows (in thousands):
| Chargebacks, Discounts for Prompt Payment and Other |  | Other Customer Credits/Fees and Co-pay Assistance |  | Rebates |  | Total
Balance at December 31, 2021 | $ | 14,625 |  |  | $ | 8,875 |  |  | $ | 24,825 |  |  | $ | 48,325 |
Provision related to sales made in: |  |  |  |  |  |  |
Current period | 355,865 |  |  | 50,312 |  |  | 143,516 |  |  | 549,693 |
Prior periods | 611 |  |  | (169) |  |  | (209) |  |  | 233 |
Payments and customer credits issued | (344,220) |  |  | (44,094) |  |  | (132,706) |  |  | (521,020) |
Balance at December 31, 2022 | 26,881 |  |  | 14,924 |  |  | 35,426 |  |  | 77,231 |
Provision related to sales made in: |  |  |  |  |  |  |
Current period | 419,975 |  |  | 56,349 |  |  | 170,788 |  |  | 647,112 |
Prior periods | 295 |  |  | (1,222) |  |  | (2,531) |  |  | (3,458) |
Payments and customer credits issued | (421,930) |  |  | (50,330) |  |  | (163,785) |  |  | (636,045) |
Balance at December 31, 2023 | $ | 25,221 |  |  | $ | 19,721 |  |  | $ | 39,898 |  |  | $ | 84,840 |
Schedule of Other Assets and Other Liabilities | Contract assets and liabilities were as follows (in thousands):
| December 31,
| 2023 |  | 2022
Contract assets(1) | $ | 1,321 |  |  | $ | 1,659 |
Contract liabilities: |  |  |
Current portion(2) | $ | 5,406 |  |  | $ | 7,488 |
Long-term portion(3) | 5,524 |  |  | 6,582 |
Total contract liabilities | $ | 10,930 |  |  | $ | 14,070 |
____________________ (1) Presented in other long-term assets in the accompanying Consolidated Balance Sheets. (2) Presented in other current liabilities in the accompanying Consolidated Balance Sheets. (3) Presented in other long-term liabilities in the accompanying Consolidated Balance Sheets.

X
- Definition Reconciliation Of Sales Discount And Allowances Reserve Balances [Table Text Block] + References No definition available. + Details
Name: | exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock
Namespace Prefix: | exel_
Data Type: | dtr-types1:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-10 + Details
Name: | us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph a -SubTopic 10 -Topic 280 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41 + Details
Name: | us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-16 Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-21 + Details
Name: | us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration